Routine

COPD

Respiratory · Respiratory
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Progressive, largely irreversible airflow obstruction from noxious-particle exposure, chiefly smoking (and biomass in India). Management targets symptoms, exacerbations and smoking cessation.

Red flags

  • Admit severe exacerbation, acidotic/worsening hypoxia, altered consciousness, poor social support or failure to respond
  • Refer respiratory for diagnostic doubt, rapid decline, cor pulmonale, LTOT assessment, suspected alpha-1 deficiency, consideration of lung-volume reduction/transplant, or frequent exacerbations despite optimal therapy

Assessment

Investigations

  • Post-bronchodilator spirometry (obstructive, limited reversibility; grade by FEV1% predicted)
  • CXR (hyperinflation, bullae, exclude cancer/other), FBC (polycythaemia/anaemia/eosinophils), BMI, ECG/echo for cor pulmonale, ABG if SpO2 low, alpha-1 antitrypsin if indicated, sputum culture in exacerbations

Management

  • Smoking cessation (biggest impact), vaccination (flu, pneumococcal, COVID), pulmonary rehab, treat comorbidities
  • Inhaled: LABA+LAMA first-line; add ICS if eosinophilia or asthmatic features/exacerbations (triple therapy)
  • Exacerbation: controlled oxygen 88-92%, nebulised bronchodilators, prednisolone 30 mg 5 days, antibiotics if purulent;
  • NIV for persistent type II failure/acidosis

Disposition

Admit severe exacerbation, acidotic/worsening hypoxia, altered consciousness, poor social support or failure to respond.

Complications & pitfalls

  • Recurrent exacerbations and hospitalisation; type II respiratory failure; cor pulmonale and right heart failure; pneumothorax from ruptured bullae; secondary polycythaemia; pneumonia; depression; cachexia; increased lung-cancer risk; death

Exam pearls

  • In acute exacerbations give controlled oxygen targeting 88-92% via a 24-28% Venturi: uncontrolled high- flow oxygen can abolish hypoxic drive and precipitate CO2 narcosis. Repeat the ABG after 30-60 minutes.
  • Monitoring & follow-up: Annual review (or 2x if severe): symptoms (mMRC/CAT), exacerbation frequency, FEV1 trend, inhaler technique, smoking status, SpO2, BMI, comorbidities. Assess for LTOT if PaO2 <=7.3 kPa stable (or <=8.0 with cor pulmonale/polycythaemia) when non-smoking; review need for rescue packs.

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.